STERIS plc (NYSE:STE) Shares Purchased by Daymark Wealth Partners LLC

Daymark Wealth Partners LLC raised its holdings in STERIS plc (NYSE:STE) by 0.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,333 shares of the medical equipment provider’s stock after buying an additional 111 shares during the quarter. Daymark Wealth Partners LLC’s holdings in STERIS were worth $6,235,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in STE. Ashton Thomas Securities LLC acquired a new stake in shares of STERIS in the third quarter worth approximately $25,000. Central Pacific Bank Trust Division acquired a new position in STERIS in the third quarter valued at $28,000. Quarry LP purchased a new stake in STERIS during the third quarter valued at about $67,000. Asset Dedication LLC increased its stake in STERIS by 54.8% during the third quarter. Asset Dedication LLC now owns 291 shares of the medical equipment provider’s stock worth $71,000 after acquiring an additional 103 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in STERIS by 45.0% during the second quarter. EverSource Wealth Advisors LLC now owns 583 shares of the medical equipment provider’s stock worth $139,000 after acquiring an additional 181 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Activity at STERIS

In related news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the sale, the senior vice president now directly owns 11,372 shares in the company, valued at $2,471,363.04. This trade represents a 12.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on STE. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and raised their target price for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Stephens restated an “overweight” rating and issued a $260.00 target price on shares of STERIS in a research note on Thursday, November 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Friday, November 8th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research note on Monday, November 18th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $262.50.

STERIS Price Performance

Shares of NYSE STE opened at $216.91 on Wednesday. The business has a 50 day simple moving average of $211.79 and a 200-day simple moving average of $224.77. STERIS plc has a twelve month low of $197.82 and a twelve month high of $248.24. The company has a market capitalization of $21.41 billion, a price-to-earnings ratio of 49.52 and a beta of 0.84. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The business had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the prior year, the firm earned $2.03 EPS. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. As a group, equities research analysts expect that STERIS plc will post 9.1 earnings per share for the current year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 19th. Investors of record on Tuesday, November 19th were issued a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 1.05%. The ex-dividend date was Tuesday, November 19th. STERIS’s dividend payout ratio (DPR) is 52.05%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.